Possible Role for Vascular Cell Proliferation in Cerebral Vasospasm After Subarachnoid Hemorrhage

Background and Purpose— During vasospasm after subarachnoid hemorrhage (SAH), cerebral blood vessels show structural changes consistent with the actions of vascular mitogens. We measured platelet-derived vascular growth factors (PDGFs) in the cerebrospinal fluid (CSF) of patients after SAH and tested the effect of these factors on cerebral arteries in vivo and in vitro. Methods— CSF was sampled from 14 patients after SAH, 6 patients not suffering SAH, and 8 normal controls. ELISA was performed for PDGF-AB, transforming growth factor-&bgr;1, and vascular endothelial growth factor. A mouse model was used to compare cerebral vascular cell proliferation and PDGF staining in SAH compared with sham-operated controls. Normal human pial arteries were incubated for 7 days in vitro, 2 groups with human blood clot and 1 with and 1 without PDGF antibodies. Results— PDGF-AB concentrations in CSF from SAH patients were significantly higher than those from non-SAH patients and normal controls, both during the first week after SAH and for all time points measured. Smooth muscle and fibroblast proliferation was observed after SAH in the mouse model, and this cellular replication was observed in conjunction with PDGF protein at the sites of thrombus. In human pial arteries, localized thrombus stimulated vessel wall proliferation, and proliferation was blocked by neutralizing antibodies directed against PDGFs. Conclusions— Vascular mitogens are increased in the CSF of patients after SAH. Proliferation of cells in the vascular wall is associated with perivascular thrombus. Cellular proliferation and subsequent vessel wall thickening may contribute to the syndrome of delayed cerebral vasospasm.

[1]  R. Tamargo,et al.  Prevention of Experimental Cerebral Vasospasm by Intracranial Delivery of a Nitric Oxide Donor From a Controlled-Release Polymer: Toxicity and Efficacy Studies in Rabbits and Rats , 2002, Stroke.

[2]  R. Tamargo,et al.  Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats. , 2002, Journal of neurosurgery.

[3]  M. McGirt,et al.  Attenuation of Cerebral Vasospasm After Subarachnoid Hemorrhage in Mice Overexpressing Extracellular Superoxide Dismutase , 2002, Stroke.

[4]  M. McGirt,et al.  Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: Methodological analysis , 2002, Neurological research.

[5]  R. Macdonald,et al.  Heme oxygenase-1 gene therapy for prevention of vasospasm in rats. , 2002, Journal of neurosurgery.

[6]  Leslie A. Smith,et al.  Protective Vasomotor Effects of In Vivo Recombinant Endothelial Nitric Oxide Synthase Gene Expression in a Canine Model of Cerebral Vasospasm , 2002, Stroke.

[7]  R. Sercombe,et al.  Cerebrovascular inflammation following subarachnoid hemorrhage. , 2002, Japanese journal of pharmacology.

[8]  John H. Zhang,et al.  Inhibitory Effect With Antisense Mitogen-Activated Protein Kinase Oligodeoxynucleotide Against Cerebral Vasospasm in Rats , 2002, Stroke.

[9]  I. Nagata,et al.  Broad-Spectrum and Selective Serine Protease Inhibitors Prevent Expression of Platelet-Derived Growth Factor-BB and Cerebral Vasospasm After Subarachnoid Hemorrhage: Vasospasm Caused by Cisternal Injection of Recombinant Platelet-Derived Growth Factor-BB , 2001, Stroke.

[10]  D. Stewart,et al.  Temporal Relationship Between Endothelin-1 Concentrations and Cerebral Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage , 2001, Stroke.

[11]  H. Nukui,et al.  Effect of a platelet-activating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage--open clinical trial to investigate efficacy and safety. , 2001, Neurologia medico-chirurgica.

[12]  P. Suter,et al.  Review of Medical Prevention of Vasospasm after Aneurysmal Subarachnoid Hemorrhage: A Problem of Neurointensive Care , 2001, Neurosurgery.

[13]  G. Murray,et al.  Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. , 2000, Journal of neurosurgery.

[14]  J. Pickard,et al.  An efficacy and safety study of the ETA/B receptor antagonist TAK-044 in subarachnoid hemorrhage , 2000 .

[15]  S. Neff,et al.  In vivo animal models of cerebral vasospasm: a review. , 2000, Neurosurgery.

[16]  T. Taniguchi,et al.  Doxorubicin, an RNA synthesis inhibitor, prevents vasoconstriction and inhibits aberrant expression of endothelin-1 in the cerebral vasospasm model of the rat , 2000, Neuroscience Letters.

[17]  R. Dacey,et al.  Molecular keys to the problems of cerebral vasospasm. , 2000, Neurosurgery.

[18]  M. Omata,et al.  Troglitazone and pioglitazone attenuate agonist‐dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells , 1999, British journal of pharmacology.

[19]  R. Armonda,et al.  Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. , 1999, Stroke.

[20]  C. Epstein,et al.  Amelioration of vasospasm after subarachnoid hemorrhage in transgenic mice overexpressing CuZn-superoxide dismutase. , 1999, Stroke.

[21]  G. Helm,et al.  Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. , 1998, Neurosurgery.

[22]  V. Seifert,et al.  Endothelin and subarachnoid hemorrhage: an overview. , 1998, Neurosurgery.

[23]  M. Schachter.  Calcium antagonists and atherosclerosis. , 1997, International journal of cardiology.

[24]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[25]  P. Huang,et al.  Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. , 1997, Circulation research.

[26]  T. Oury,et al.  Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[27]  L. Katwa,et al.  The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. , 1996, Journal of molecular and cellular cardiology.

[28]  J. Torner,et al.  Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. , 1995, Critical care medicine.

[29]  T. Tada,et al.  Elevation of Transforming Growth Factor‐&bgr;1 Level in Cerebrospinal Fluid of Patients With Communicating Hydrocephalus After Subarachnoid Hemorrhage , 1994, Stroke.

[30]  R. Spetzler,et al.  The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. , 1993, Neurological research.

[31]  Peter Harrison,et al.  Platelet a-granules , 1993 .

[32]  M. Mayberg,et al.  Morphologic changes in cerebral arteries after subarachnoid hemorrhage. , 1990, Neurosurgery clinics of North America.

[33]  T. Sundt,et al.  Alterations of mechanical properties in canine basilar arteries after subarachnoid hemorrhage. , 1989, Journal of neurosurgery.

[34]  R. R. Smith,et al.  Arterial wall changes in early human vasospasm. , 1985, Neurosurgery.

[35]  F. Tancioni,et al.  Platelet derived growth factor and subarachnoid haemorrage: A study on cisternal cerebrospinal fluid , 2005, Acta Neurochirurgica.

[36]  H. Nukui,et al.  Effect of a Platelet-Activating Factor Receptor Antagonist , E 5880 , on Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage — Open Clinical Trial to Investigate Efficacy and Safety — , 2004 .

[37]  J. Achard,et al.  Safety of Intraventricular Sodium Nitroprusside and Thiosulfate for the Treatment of Cerebral Vasospasm in the Intensive Care Unit Setting , 2002 .

[38]  R. Macdonald,et al.  Pathophysiology and molecular genetics of vasospasm. , 2001, Acta neurochirurgica. Supplement.

[39]  K. Nozaki,et al.  In vivo animal models of cerebral vasospasm: a review. , 2001, Acta neurochirurgica. Supplement.

[40]  R. Tamargo,et al.  Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. , 1999, Stroke.

[41]  Sandra R. Smith,et al.  Growth factor effects on cells of the vascular wall: a survey. , 1993, Growth factors.

[42]  B. Westermark,et al.  Biology of platelet-derived growth factor , 1993 .

[43]  J. McPherson,et al.  Differences in the biological activities of transforming growth factor-beta and platelet-derived growth factor in vivo. , 1991, Growth factors.

[44]  Cerebral vasospasm. , 1990, Neurosurgery clinics of North America.

[45]  Fisher Cm,et al.  Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. , 1980, Neurosurgery.